as 05-10-2024 4:00pm EST
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
Founded: | 2014 | Country: | United States |
Employees: | N/A | City: | SAN DIEGO |
Market Cap: | 5.5B | IPO Year: | N/A |
Target Price: | $6.00 | AVG Volume (30 days): | 7.3M |
Analyst Decision: | Hold | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.09 | EPS Growth: | N/A |
52 Week Low/High: | $1.25 - $10.53 | Next Earning Date: | 05-09-2024 |
Revenue: | $302,000 | Revenue Growth: | -48.46% |
Revenue Growth (this year): | 1487.46% | Revenue Growth (next year): | 774.76% |
IBRX Breaking Stock News: Dive into IBRX Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Business Wire
5 days ago
Business Wire
10 days ago
Business Wire
12 days ago
Business Wire
17 days ago
Yahoo Finance Video
19 days ago
Business Wire
19 days ago
Business Wire
2 months ago